ALK-Abelló A/S
AKBLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.1B
Close$
$8.69
76.2% downside
Current Fair Value
76.2% downsideOvervalued by 76.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.10 Billion |
|---|---|
| Enterprise Value | $6.79 Billion |
| Annual dividend | $0.24 |
| Dividend yield | 0.66% |
| Earnings per Share | $5.41 |
| Beta | 0.71 |
| Outstanding Shares | 221,879,092 |
Return
| Return on Equity | 19.53% |
|---|---|
| Return on Assets | 13.94% |
| Return on Invested Capital | 22.33% |
Valuation & Multiples
| P/E Ratio | 39.8 |
|---|---|
| PEG | 137.74 |
| Price to Sales | 1.22 |
| Price to Book Ratio | 1.18 |
| Enterprise Value to Revenue | 0.99 |
| Enterprise Value to EBIT | 3.68 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$0.23
Consensus analyst estimateRevenue Estimate
$266.40 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
$0.26
Consensus analyst estimateRevenue Estimate
$262.82 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ALK-Abelló A/S
2,721 employees
CEO: Peter Halling
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe,...